DOCSLIB.ORG

Zoznam Publikačnej Činnosti Prof. Mudr. Vladimír Krčméry, Drsc

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Zoznam Publikačnej Činnosti Prof. Mudr. Vladimír Krčméry, Drsc Zoznam publikačnej činnosti prof. MUDr. Vladimír Krčméry, DrSc. AAB Vedecké monografie vydané v domácich vydavateľstvách AAB01 Čatár, Gustáv [UKOLF] (34%) - Krčméry, Vladimír [UKOEXFL] (33%) - Sobota, Koloman [UKOLF] (33%): Aktuálne farmakoterapeutiká 4 : antiparazitiká. - Martin : Osveta, 1991. - 182 s. ISBN 80-217-0282-6 Haľko, Jozef [rec.] Valent, Michal [rec.] Ohlasy (4): [o4] 1994 Gáliková, E. - Čáp, J. - Žigová, A. - Škráčiková, J.: Slov. Lek., roč. 4, č. 1-2, 1994, s. 12-14 [o4] 1994 Škračiková, J. - Lengyelová, Ľ. - Gáliková, E.: Slov. Lek., roč. 4, č. 8, 1994, s. 9-10 [o3] 1997 Slezák, R. - Dřízal, I. - Horáček, J. - Kopecký, O.: Infekční choroby ústní sliznice. Praha : Garda, 1997, s. 166 [o4] 1999 Szilágyiová, M.: Importované parazitárne nákazy. Martin : Beriss, 1999, s. 151 AAB02 Krčméry, Vladimír [UKOEXFL] (5%) - Granninger, W. - Adam, D. - Sanford, J. - Abramovicz, M. - Pašteková, K. - Černý, J. - Dropčo, I. - Krčméry, Silvester - Trupl, Jan - Danišovičová, A. - Hricák, V. - Bajan, A. - Bálint, Ondrej [UKOLF] - Hruškovič,I. - Kriška, Milan [UKOLF] - Štefanovič, Ján [UKOLF] - Makai, František [UKOLF] - Mardiak, Jozef [UKOLF2ONK] - Štencl, Ján: Manuál antimikrobiálnej chemoterapie. - 1. vyd. - Martin : Osveta, 1993. - 301 s. ISBN 80-217-0511-6 Nosáľová, G. [rec.] Tomášik, E. [rec.] AAB03 Krčméry, Vladimír [UKOEXFL] (33%) - Špánik, Stanislav [UKOEXFL] - Danišovičová, A.: Chemoterapia infekcií u imunodeficientných stavov. - Bratislava : IVZ, 1993. - 115 s. ISBN 80-7163-003-9 AAB04 Krčméry, Vladimír [UKOEXFL] (21,2%) - Granninger, W. (7,5%) - Adam, D. (4,1%) - Sanford, J. (2,6%) - Abramovicz, M. (1,7%) - Pašteková, K. (0,4%) - Černý, J. (3,3%) - Dropčo, I. (0,8%) - Ďuriš, Ivan [UKOLF] (1,1%) - Krčméry, Silvester [UKOLFKGM](14,1%) - Trupl, Jan (3,4%) - Danišovičová, A. (1,9%) - Hricák, Vasiľ (7,3%) - Bajan, A. (2,1%) - Bálint, Ondrej [UKOLF] (1,3%) - Hruškovič, I. (0,7%) - Kriška, Milan [UKOLF] (5,6%) - Makai, František [UKOLF] (0,9%) - Mardiak, Jozef [UKOLF2ONK] (3,5%) - Mateička, F. (1,8%) - Špánik, Stanislav [UKOEXFL] (6,2%) - Štencl, J. (2,7%) - Šulcová, M. (1,1%) - Krčméry, Vladimír (4,7%): Manuál antimikrobiálnej chemoterapie. - 2. dopl. vyd. - Martin : Osveta, 1998. - 277 s. ISBN 80-88824-86-9 Bálint, O. [rec.] Tomášik, E. [rec.] \4 675 Ohlasy (2): [o4] 2003 Mikulaj, V.: Uroinfekcie u žien. Bratislava : Lukspress, 2003, s. 229 [o4] 2015 Kajtár, P.: Via practica, roč. 12, č. 2, 2015, s. 64-70 AAB05 Jurga, Ľudovít - Adam, Zdeněk - Bilder, Josef - Demitrovičová, Andrea - Hrstková, Hana - Kliment, Ján [UKOLJ151] - Kopečný, Jiří - Kostřica, Rom - Koza, Ivan - Krahulcová, Eva - Král, Zdeněk - Krčméry, Vladimír [UKOEXFL] (4%) - Kubešová, Hana - Lešník, František - Maňka, Ivan - Matula, Pavel - Mayer, Jiří - Novák, Jaroslav - Ondruš, Dalibor [UKOLFONU] - Pačovský, Zdeněk - Pleško, Ivan - Pospíšilová, Ivona - Skříčková, Jana - Ševčík, Pavel - Valanský, Ladislav - Vášová, Ingrid - Vermousek, Ivan -Vorlíček, Jiří - Vyzula, Rostislav - Žaloudík, Jan: Klinická onkológia a rádioterapia. - 1. vyd. - Bratislava : Slovak Academic Press, 2000. - 1030 s. Literárny fond udeľuje za túto knihu "Prémiu za vedeckú a odbornú literatúru za rok 2000" v kategórii prírodných vied Prof. MUDr. Ľudovítovi Jurgovi, DrSc. a kolektívu Literatúra, register ISBN 80-88908-71-X Ševčíková, Ľudmila [rec.] Macháček, Jiří [rec.] Ohlasy (23): 1 [o4] 2004 Királová, A. - Vajíčeková, J. - Straková, A.: Lymfedém - interdisciplinárny problém. In: Slovenský lekár, roč. 14 (28), č. 5-6, 2004, s. 132-134 [o3] 2005 Mladosievičová, B. - Fotlinová, A. - Wawruch, M.: Genetické testy v predikcii účinnosti a toxicity chemoterapie u onkologických pacientov. In: Vnitřní lékařství, roč. 51, č. 5, 2005, s. 560-565 [o4] 2005 Kocsisová, A. - Hrubý, R.: Edukácia pacienta s nádorovým ochorením hrtana. In: Sestra, roč. 4, č. 7-8, 2005, s. 18-19 [o4] 2005 Vrublová, Y.: Analýza potřeb u žen při chemoterapii onkogynekologického onemocnění. In: Ošetrovateľstvo 21. storočia v procese zmien. Nitra : Univerzita Konštantína Filozofa, 2005, S. 538 [o4] 2006 Péč, M. - Dobiáš, J. - Mušák, Ľ. - Péčová, R. - Hajtmanová, E. - Jautová, J. - Jakubovič, I. - Poláček, H.: Lekárska biológia pre študijný odbor rádiologická asistencia. Martin : UK JLF, 2006, S. 129 [o4] 2006 Šoltésová, S.: Komplexná ošetrovateľská starostlivosť o pacienta s kolorektálnym karcinómom na oddelení rádioterapie. In: Ošetrovateľstvo a pôrodná asistencia, roč. 4, č. 2, suppl., 2006, s. 4-7 [o4] 2006 Matulová, Z.: Strach chorých s onkologickým ochorením. In: Ošetrovateľstvo a pôrodná asistencia, roč. 4, č. 2, suppl., 2006, s. 8-12 [o4] 2006 Šajter, V. - Turecký, L. - Kadlečík, R. - Bořuta, P.: Biofyzika, biochémia a rádiológia. Martin : Osveta, 2006, S. 263 [o4] 2007 Bašková, M. - Rudolfová, K.: Význam edukácie pri prevencii ... In: Ošetrovateľstvo a pôrodná asistencia, roč. 5, č. 2, suppl., 2007, s. 7-9 [o4] 2008 Zámečníková, E.: Prevencia karcinómu prsníka. In: Sestra, roč. 7, č. 7-8, 2008, s. 28-29 [o4] 2007 Obročníková, A. - Majerníková, Ľ. - Jakabovičová, A.: Význam prevencie nádorového ... In: MOLISA 4. Medicínsko-ošetrovateľské listy Šariša. Prešov : Prešovská Univerzita, 2007, S. 136 [o4] 2008 Hudáková, Z. - Fialová, A. - Kokoruďová, J. - Kožíková, A. - Krupová, D. - Kundisová, J. - Zavacká, A.: Onkologické ošetrovateľstvo. Martin : Osveta, 2008, S. 140 [o4] 2009 Tirpáková, M. - Bernasovská, K.: Rizikové faktory detských nádorov. In: Kvalita života a zdravia. Bratislava : Vysoká škola zdravotníctva a sociálnej práce sv. Alžbety, 2009, S. 431 [o4] 2009 Tirpáková, M.: Etiológia nádorov v detskom veku. In: Detský lekár, roč. 16, č. 3, 2009, s. 91-93 a 100 [o4] 2009 Tirpáková, M. - Bernasovská, K.: Riziká vzniku onkologických ... In: Szárazová, M. - Kavcová, E. - Janušová, T.: Podpora zdravia, prevencia a hygiena v teórii a praxi - VI. Martin : Jesseniova lekárska fakulta v Martine, 2009, S.144 [o4] 2009 Višňovcová, N. - Jakušová, V. - Jakuš, J.: Manažment ochrany zdravia ... In: Szárazová, M. - Kavcová, E. - Janušová, T.: Podpora zdravia, prevencia a hygiena v teórii a praxi - VI. Martin : Jesseniova lekárska fakulta v Martine, 2009, S. 373 [o4] 2010 Lučenič, A.: Permanentná brachyterapia lokalizovaného ... In: Onkológia, roč. 5, suppl. 1, 2010, s. 31-32 [o4] 2010 Višňovcová, N. - Tonhajzerová, I. - Jakušová, V.- Baráni, H. - Jakuš, J.: Rádioterapia a včasné postradiačné ... In: Onkológia, roč. 5, č. 5, 2010, s. 292-295 [o4] 2010 Salát, D. - Kopecká, I.: Fajčenie, chronická obštrukčná choroba ... In: Kavcová, E. - Halašová, E. - Dzian, A.: Karcinóm pľúc. Martin : JLF UK, 2010, S. 625 [o4] 2010 Palkechová, Z. - Matulová, Z.: Kvalita života pacientov ... In: Ošetrovateľský obzor, roč. 7, č. 4-5, 2010, s. 82-83 [o4] 2010 Palková, Ľ. - Berč, A. - Andrašina, I. - Bérešová, M. - Dimunová, L. - Kalátová, D. - Poľanská, J. - Šramka, M. - Vančo, M. - Vyšňanová, M. - Wagnerová, M.: Onkologické ošetrovateľstvo 2. Košice : ZZ design studio - Ing. ZvonimírZÁVIŠ, 2010, S. 159 [o4] 2011 Višňovcová, N. - Jakušová, V. - Jakuš, J.: Manažment plánovania liečby ... In: Podpora zdravia, prevencia a hygiena v teórii a praxi - 7. Martin : JLF UK, 2011, s. 418-423 [o3] 2011 Višňovcová, N. - Jakušová, V. - Jakuš, J.: Problematika včasných zmien na koži ... In: Praktická radiologie, roč. 16, č. 1, 2011, s. 16-18 AAB06 Kriška, Milan [UKOLF] - Ambrózy, Ewald - Bada, Viliam [UKOLF3IK] - Benetin, Ján [UKOLF] (2%) - Bilický, Jozef [UKOLF1RK] - Biss, Branislav - Borovský, Miroslav [UKOLF1GK] - Božeková, Lýdia [UKOLF] - Breza, Ján [UKOLFURK] - Buc, Milan [UKOLFIU] - Danilla, Tibor [UKOLFDDK] - Dukát, Andrej [UKOLF2IK] - Ďuriš, Ivan [UKOLF] - Ďurišová, Alena - Edelsteinová, Soňa - Foltán, Viliam [UKOFAPR] - Gajdošík, Ján - Gibala, Pavol - Haľko, Jozef - Hatala, Róbert - Hegyi, Ladislav - Jánoška, Stanislav - Ježová,Daniela - Kern, Peter - Kořínková, Viera [UKOLFPK] - Krčméry, Vladimír [UKOEXFL] (2%) - Kristová, Viera [UKOLFFAU] (2,8%) - Krištúfek, P. - Kuchar, Marian [UKOEXFL] - Kupčová, Viera [UKOLF3IK] - Laššánová, Monika [UKOLFFAU] - Lednár, Miroslav - Magulová,Lívia [UKOEXAF] (2,5%) - Mahrla, Zdenko - Martinka, Emil - Michalko, Ľubomír [UKOLF] - Mikeš, Zoltán [UKOLF] - Murín, Ján [UKOLF1IK] - Novotný, Vladimír [UKOLFPK] - Payer, Juraj [UKOLF5IK] - Remková, Anna [UKOLF] - Riečanský, Igor - Rovenský, Jozef - Rybár, Ivan [UKOPRCAL] - Sirotiaková, Jana - Slaný, Jozef - Šréter, Ivan - Štvrtinová, Viera [UKOLF2IK] - Turčáni, Peter [UKOLF1NK] - Vavrečka, Anton - Višňovský, Peter - Vozár, Juraj: Memorix klinickej farmakológie. - 1. vyd. - Bratislava : SAP, 2002. - 879 s. ISBN 80-88908-90-6 2 Dzúrik, R. [rec.] Švihovec, J. [rec.] Ohlasy (39): [o4] 2002 Švec, P.: Slovakofarma revue, roč. 12, č. 1, 2002, s. 4 [o4] 2002 Pásztor, L.: Medicínsky monitor, č. 3, 2002, s. 12 [o4] 2002 Gavorník, P.: Všeobecná angiológia, roč. 2, č. 2, 2002, s. 66 [o6] 2002 Bernadič, M.: Praktická gynekológia, roč. 9, č. 1, 2002, s. 51 [o6] 2002 Bernadič, M.: Psychiatria, roč. 9, č. 1, 2002, s. 44 [o6] 2002 Bernadič, M.: Rheumatologia, roč. 16, č. 1, 2002, s. 6 [o6] 2002 Bernadič, M.: Naša univerzita, roč. 48, č. 6, 2002, s. 11 [o4] 2003 Mikulaj, V.: Uroinfekcie u žien. Bratislava : Luskpress, 2003, s. 228 [o4] 2003 Fülöpová, A. - Hnatová, E. - Fülöp, P. - Pavlušová, M.: Medicínsky monitor, č. 2, 2003, s. 12 [o4] 2003 Luknárová, N. - Henčová, B.: Derma, roč. 3, č. 3, 2003, s. 24 [o4] 2003 Gavorník, P. - Bremserová, E. - Pilarčíková, A.: Medicina militaris Slovaca, roč. 5, č. 1, 2003, s. 37 [o4] 2003 Meluzínová, H. - Weber, P. - Kubešová, H.: Lekársky obzor, roč. 52, č. 10,
Load more

Recommended publications
  • Diagnostic Accuracy of Procalcitonin in Critically Ill Immunocompromised
    Bele et al. BMC Infectious Diseases 2011, 11:224 http://www.biomedcentral.com/1471-2334/11/224 RESEARCHARTICLE Open Access Diagnostic accuracy of procalcitonin in critically ill immunocompromised patients Nicolas Bele1, Michael Darmon1,2,3, Isaline Coquet1, Jean-Paul Feugeas4, Stéphane Legriel1, Nadir Adaoui4, Benoît Schlemmer1 and Élie Azoulay1* Abstract Background: Recognizing infection is crucial in immunocompromised patients with organ dysfunction. Our objective was to assess the diagnostic accuracy of procalcitonin (PCT) in critically ill immunocompromised patients. Methods: This prospective, observational study included patients with suspected sepsis. Patients were classified into one of three diagnostic groups: no infection, bacterial sepsis, and nonbacterial sepsis. Results: We included 119 patients with a median age of 54 years (interquartile range [IQR], 42-68 years). The general severity (SAPSII) and organ dysfunction (LOD) scores on day 1 were 45 (35-62.7) and 4 (2-6), respectively, and overall hospital mortality was 32.8%. Causes of immunodepression were hematological disorders (64 patients, 53.8%), HIV infection (31 patients, 26%), and solid cancers (26 patients, 21.8%). Bacterial sepsis was diagnosed in 58 patients and nonbacterial infections in nine patients (7.6%); 52 patients (43.7%) had no infection. PCT concentrations on the first ICU day were higher in the group with bacterial sepsis (4.42 [1.60-22.14] vs. 0.26 [0.09- 1.26] ng/ml in patients without bacterial infection, P < 0.0001). PCT concentrations on day 1 that were > 0.5 ng/ml had 100% sensitivity but only 63% specificity for diagnosing bacterial sepsis. The area under the receiver operating characteristic (ROC) curve was 0.851 (0.78-0.92).
    [Show full text]
  • Polymicrobial Septic Shock with Multiorgan Dysfunction in An
    JOMA Polymicrobial Septic Shock10.5005/jp-journals-100 with Multiorgan Dysfunction70-0012 CASE REPORT Polymicrobial Septic Shock with Multiorgan Dysfunction in an Otherwise Healthy Immunocompetent Patient 1Anuradha Makkar, 2Inam D Khan, 3KS Rajmohan, 4Syed A Hashmi, 5Lakshmi Nair, 6Alpana Gupta, 7Harleen Chopra, 8Priyanka Banerjee, 9Pragyan S Panda, 10Rajiv M Gupta ABSTRACT Source of support: Nil Background: Sepsis is a significant cause of morbidity and Conflict of interest: None mortality worldwide despite advanced critical life-support. Septic shock and multiorgan dysfunction is the terminal stage INTRODUCTION in critically ill patients leading to perfusion abnormalities, lactic acidosis, oliguria and altered mental status creating a rapid Sepsis is a major cause of morbidity and mortality world- downhill course and mortality. Sepsis ensues through stages wide despite advanced critical life-support. It is the 11th - of exaggerated immune response including systemic inflamma leading cause of death overall with attributable mortality tory response syndrome, in the backdrop of infectious stimuli. to sepsis and severe sepsis being 30 to 50% and 50 to 60%. Case report: Polymicrobial septic shock with multiorgan Following a non-infectious or infectious insult, there is dysfunction leads to demise in an otherwise healthy immuno- competent patient. Microbiological profile revealedEscherichia a preliminary systemic response which becomes over- coli urinary tract infection (UTI), Staphylococcus sciuri bactere- whelming leading to systemic inflammatory response mia, Acinetobacter baumanii ventilator-associated pneumonia, syndrome. When the compensatory anti-inflammatory and central line catheter tip Pseudomonas aeruginosa, thereby reaction fails, it leads to immunomodulatory failure, pointing towards polymicrobial sepsis. Neutropenia of 290/ dL along with serum procalcitonin 5 ng/mL was detected.
    [Show full text]
  • Program: 2Nd Annual Global AYA Cancer Congress Atlanta 2017
    THE 2nd GLOBAL ADOLESCENT & YOUNG ADULT CANCER CONGRESS | DECEMBER 5 - 7, 2017 ATLANTA, GA, USA CONTENTS USA PLANNING COMMITTEE PAGE NO: l Simon Davies, Co-Chair l Stuart Siegel, Co-Chair WELCOME FROM THE HOSTS 4 - 5 l Archie Bleyer l Damon Reed GENERAL INFORMATION 6 - 7 l Rebecca Block l Nita Seibel INSTRUCTIONS TO PRESENTERS l Lindsay Frazier l Pam Simon 6 l Hilary Gan l Sam Watson SOCIAL PROGRAM 7 l Brandon Hayes-Lattin l Brad Zebrack l John Perentesis DAY BY DAY PROGRAM 8 - 10 INTERNATIONAL ADVISORS SPEAKER BACKGROUNDS 11 - 25 US POSTER LISTING 26 - 32 l Karen Albritton l Leonard Sender l Gerald Grant l Glenn Taylor GLOBAL EXCHANGE LISTING 33 l Rebecca Johnson l Kate Yglesias Houghton l John Letterio AUTHORS’ INDEX 34 - 38 CANADA ORAL PRESENTATION ABSTRACTS 40 - 41 l Ronald Barr POSTER PRESENTATION ABSTRACTS 41 - 95 ITALY LATE BREAKER ABSTRACTS l Andrea Ferrari 96 AUSTRALIA ACKNOWLEDGMENTS 97 l Antoinette Anazodo l Pandora Patterson BACKGROUND TO PARTNERS, SUPPORTERS AND EXHIBITORS 98 -108 l Peter Orchard l David Thomas FRANCE THANKS 109 l Laurence Brugieres l Valerie Laurence EXHIBIT HALL LAYOUT 110 INDIA SAVE THE DATE 2018 Inside back page l Prakash Chitalkar UK l Maria Cable l Sue Morgan The AYA Global Accord is a collaboration between three l Lorna Fern l Sam Smith charitable organizations: Teen Cancer America, Teenage l Simon Fuller l Daniel Stark Cancer Trust and CanTeen Australia. Together they have l Faith Gibson l Jeremy Whelan developed an annual event that will rotate between the UK, USA and Australia. We hope it will become the most GERMANY important event for professionals working in the AYA field.
    [Show full text]
  • Candidatos Em Ordem Alfabética Por Cargo Edital: 42/Smad/2019 Nº Insc
    EDITAL Nº 053/SMAd/2019 “DISPÕE SOBRE A HOMOLOGAÇÃO DAS INSCRIÇÕES E ABRE PRAZO PARA RECURSO.” MAURICIO FRIZZO LOUREIRO, Presidente do Legislativo no exercício do cargo de Prefeito Municipal de Santo Ângelo, Estado do Rio Grande do Sul, no uso de suas atribuições legais, torna público aos interessados as INSCRIÇÕES HOMOLOGADAS do Concurso Público para Provimento de Cargos, de acordo com o Edital nº 42/SMAd/2019, conforme relação anexa, abrindo prazo para recurso nos dias 29, 30 e 31 de julho de 2019, exclusivamente pela internet, através de link disponível no sítio www.santoangelo.uri.br/extensao. GABINETE DO PREFEITO DE SANTO ÂNGELO/RS, 26 DE JULHO DE 2019. Mauricio Frizzo Loureiro Presidente do Legislativo no exercício do cargo de Prefeito Registre-se e Publique-se CONCURSO PÚBLICO DESTINADO AO PROVIMENTO DE CARGOS - PREFEITURA MUNICIPAL DE SANTO ÂNGELO/RS Candidatos em Ordem Alfabética por Cargo Edital: 42/SMAd/2019 Nº Insc. Nome: Doc. Ident. CARGO: 1 - ADMINISTRADOR 7.946 ABEL STIELER MARCIANO 4090567274 8.553 ALEX BARCELOS ROBALO 5080241952 8.874 ALEXANDRE RODRIGUES DOCKHORN 3027913197 7.888 ALINE QUEIRÓS DA FONSECA PRETTO 1094150801 1.367 ANA CRISTINA BARROS DE ALMEIDA 6050351748 7.104 ANDERSON DANIEL STOCHERO 3069370504 4.124 ANDERSON LUIS BURKHARD 6098237222 4.027 ANDREA MARIA CACENOTE 1057732537 1.480 ANDREIA ANDRADE CICHORSKI 3079661066 6.228 BRUNO GUIMARAES MUNHOZ 3081964219 324 CARLOS DANIEL SCHUMACHER JUNIOR 7073061827 7.908 CARLOS ROBERTO DE LIMA 4042350721 sexta-feira, 26 de julho de 2019 Página 1 de 195 Candidatos em Ordem Alfabética por Cargo Edital: 42/SMAd/2019 Nº Insc. Nome: Doc.
    [Show full text]
  • Annual Meeting
    Volume 97 | Number 5 Volume VOLUME 97 NOVEMBER 2017 NUMBER 5 SUPPLEMENT SIXTY-SIXTH ANNUAL MEETING November 5–9, 2017 The Baltimore Convention Center | Baltimore, Maryland USA The American Journal of Tropical Medicine and Hygiene The American Journal of Tropical astmh.org ajtmh.org #TropMed17 Supplement to The American Journal of Tropical Medicine and Hygiene ASTMH FP Cover 17.indd 1-3 10/11/17 1:48 PM Welcome to TropMed17, our yearly assembly for stimulating research, clinical advances, special lectures, guests and bonus events. Our keynote speaker this year is Dr. Paul Farmer, Co-founder and Chief Strategist of Partners In Health (PIH). In addition, Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, will deliver a plenary session Thursday, November 9. Other highlighted speakers include Dr. Scott O’Neill, who will deliver the Fred L. Soper Lecture; Dr. Claudio F. Lanata, the Vincenzo Marcolongo Memorial Lecture; and Dr. Jane Cardosa, the Commemorative Fund Lecture. We are pleased to announce that this year’s offerings extend beyond communicating top-rated science to direct service to the global community and a number of novel events: • Get a Shot. Give a Shot.® Through Walgreens’ Get a Shot. Give a Shot.® campaign, you can not only receive your free flu shot, but also provide a lifesaving vaccine to a child in need via the UN Foundation’s Shot@Life campaign. • Under the Net. Walk in the shoes of a young girl living in a refugee camp through the virtual reality experience presented by UN Foundation’s Nothing But Nets campaign.
    [Show full text]
  • Procalcitonin and Its Limitations: Why a Biomarker's Best Isn't Good Enough
    POINT/COUNTERPOINT Counterpoint Procalcitonin and Its Limitations: Why a Biomarker's Best Isn't Good Enough Ayesha Farooq1 and Jessica M. Colón-Franco1* Sepsis-related conditions remain the leading Intended uses now include supporting antibiotic Downloaded from https://academic.oup.com/jalm/article/3/4/716/5603063 by guest on 23 September 2021 causes of mortality, morbidity, and expenditures management decisions in respiratory infections worldwide despite efforts to standardize care and and sepsis. There is no reference method for PCT. expedite diagnosis and treatment, which are de- The BRAHMS Kryptor sensitive PCT assay (Thermo- terminants of outcome. As with most syndromes Fisher Scientific) and its predecessor were initially with complex pathophysiology, no gold standard available and used to derive PCT cutoffs. The diagnostic test exists. Diagnosis is complicated by BRAHMS assay can be run in automated immuno- nonspecific symptoms and lengthy blood cultures assay instruments from partner companies. Simi- with high false-negative rates. Empiric antibiotic larly, the Diazyme PCT immunotubidimetric assay treatment upon signs of sepsis is an increasing (Diazyme Laboratories) can be implemented in concern for antibiotic overuse and resistance. The common chemistry analyzers. This widespread need for biochemical biomarkers for sepsis diag- availability of PCT assays is facilitating clinical use nosis is well accepted. Several pro- and antiinflam- but analytical considerations come into play. The matory biomarkers have been investigated, but functional sensitivity of the Diazyme PCT assay is only few are incorporated in clinical practice (1). higher than the BRAHMS assay and above the Procalcitonin (PCT)2 is one such molecule that reference interval of healthy individuals (2, 3).
    [Show full text]
  • Procalcitonin (PCT)
    Procalcitonin (PCT) Guidance Background: Up to 50% of antimicrobial use in the inpatient setting is unneeded or inappropriate.1 For example, viruses are typically the cause of acute bronchitis but despite this as much as 80% of patients will be prescribed antibiotics.2 Also the length of treatment for most infections has been poorly studied and it is likely that treatment durations are inappropriately long.3 The appropriate use of antimicrobials is essential because they are associated with patient harm including drug toxicity, increased drug resistance, and collateral damage such as Clostridium diffiicile-associated diarrhea.4-6 Procalcitonin has been evaluated as a biomarker to assist the clinician in the diagnosis and treatment of bacterial infection. Procalcitonin has been studied most thoroughly for lower respiratory tract infections and sepsis and its use is associated with decreased antimicrobial usage without worsening of clinical outcomes.7-13 What is Procalcitonin?14-16 Procalcitonin (PCT) is a 116 amino acid precursor of calcitonin which under normal circumstances is produced by the thyroid C-cells. Serum concentrations of PCT are normally <0.05 ng/mL but in circumstances of systemic inflammation, particularly bacterial infection, PCT is produced in large quantities by many body tissues. It is detectable within 2-4 hours and peaks within 6-24 hours (as opposed to CRP which begins to rise after 12-24 hours and peaks at 48 hours). 14-16 PCT production is not impaired by neutropenia or other immunosuppressive states. PCT levels parallel the severity of the inflammatory insult or infection meaning those with more severe disease have higher levels.
    [Show full text]
  • CUNY Baccalaureate for Unique and Interdisciplinary Studies
    Greetings from the President May 30, 2018 Dear Graduates: Congratulations! You have reached a most significant milestone in your life. Your hard work, determination, and commitment to your education have been rewarded, and you and your loved ones should take pride in your accomplishments and successes. Hunter College certainly takes pride in you. ' Your Hunter education has prepared you to meet the challenges of a world that is rapidly changing politically, socially, economically, ~ . technologically. As part of the next generation of thoughtful, responsible, and intelligent leacfets;·: you will make a real difference wherever you apply your knowledge and skills. Endless 'Opportunities await you. As you pursue your goals and move forward with your professional and personal lives., please carry with you Hunter's commitment to community, diversity, and service to others. We look forward to hearing great things about you, and we hope you will stay connected to the exciting activities and developments on campus. Please remember Hunter College and know that you will always be part of our family. Best wishes for continued success. Sincerely, ~vi Jennifer J. Raab President Order ofExercises Presiding Jennifer J. Raab, President Eija Ayravainen, Vice President for Student Affairs and Dean ofStudents Opening Ceremony Michael F. Mazzeo, Macaulay Honors College, Bachelor ofArts '18 Processional President's Party and Members of the Faculty Graduates and Candidates for Graduation National Anthem Joanna Malaszczyk, Master ofArts '18 Bagpiper Ian A. Sherman, Doctor ofNursing Practice '18 Greetings William C. Thompson, Jr., Chair, Board ofTrustees of The City University ofNew York Matthew Sapienza, Senior Vice Chancellor and ChiefFinancial Officer of The City University ofNew York ' Charge to the Graduates and Candidates for Graduation President Jennifer J.
    [Show full text]
  • Procalcitonin and C-Reactive Protein in the Diagnosis of Spontaneous Bacterial Peritonitis
    10 Original Article Procalcitonin and C-reactive protein in the diagnosis of spontaneous bacterial peritonitis Rajanshu Verma1, Sanjaya K. Satapathy2,3, Muhammad Bilal4 1Transplant Hepatology/Gastroenterology fellow, University of Tennessee Health Sciences Center, Memphis, TN, USA; 2Department of Transplant Surgery, Methodist University Hospital Transplant Institute/University of Tennessee Health Sciences Center, Memphis, TN, USA; 3Medical Director of Liver Transplantation, Division of Hepatology, Sandra Atlas Bass Center for Liver Diseases and Liver Transplantation, Northwell Health/North Shore University Hospital, Manhasset, New York, USA; 4Department of Gastroenterology, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA Contributions: (I) Conception and design: M Bilal; (II) Administrative support: SK Satapathy, M Bilal; (III) Provision of study materials or patients: M Bilal; (IV) Collection and assembly of data: M Bilal, R Verma; (V) Data analysis and interpretation: R Verma, SK Satapathy; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Muhammad Bilal, MD. Department of Gastroenterology, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA. Email: [email protected]. Background: Spontaneous bacterial peritonitis (SBP) is a serious complication of cirrhosis and is associated with high morbidity and mortality. Rapid institution of appropriate antibiotics is central to the improved patient outcome. Correctly obtaining ascites fluid for analysis has several technical and logistic limitations resulting in overuse of empiric antibiotics when patients are admitted to the hospital with suspected SBP. Procalcitonin and C-reactive protein (CRP) are non-invasive markers of infection. We conducted a study to illustrate the role of these markers in making the diagnosis of SBP in patients with cirrhosis.
    [Show full text]
  • Edital Nº 68/2019, 13 De Setembro De 2019. “Dispõe Sobre a Divulgação Do Resultado Preliminar De Notas Das Provas Escritas
    EDITAL Nº 68/2019, 13 DE SETEMBRO DE 2019. “DISPÕE SOBRE A DIVULGAÇÃO DO RESULTADO PRELIMINAR DE NOTAS DAS PROVAS ESCRITAS DO CONCURSO PÚBLICO RELATIVO AO EDITAL nº 42/SMAd/2019, E DÁ OUTRAS PROVIDÊNCIAS.” Jacques Gonçalves Barbosa, Prefeito Municipal de Santo Ângelo, Estado do Rio Grande do Sul, no uso de suas atribuições legais, torna público aos interessados, o RESULTADO PRELIMINAR DE NOTAS das provas escritas do Concurso Público para Provimento de Cargos relativo ao Edital nº 42/SMAd/2019, abrindo prazo para recurso nos dias 16, 17 e 18 de setembro de 2019, exclusivamente pelo site http://www.santoangelo.uri.br/extensao/. GABINETE DO PREFEITO MUNICIPAL DE SANTO ÂNGELO, 13 DE SETEMBRO DE 2019. Jacques Gonçalves Barbosa Prefeito Registre-se e Publique-se URI Santo Ângelo-RS - Avaliação de Concursos RESULTADO PRELIMINAR DO CONCURSO PÚBLICO DESTINADO AO PROVIMENTO DE CARGOS - PREFEITURA MUNICIPAL DE SANTO ÂNGELO/RS Edital de Concurso: Nº 42/SMAd/2019 Cargo: 1-Administrador Inscrição Nome do Candidato Nota 7.946 ABEL STIELER MARCIANO 69,50 8.553 ALEX BARCELOS ROBALO 77,50 8.874 ALEXANDRE RODRIGUES DOCKHORN 66,00 7.888 ALINE QUEIRÓS DA FONSECA PRETTO 65,00 1.367 ANA CRISTINA BARROS DE ALMEIDA 86,00 Página 1 de 290 URI Santo Ângelo-RS - Avaliação de Concursos RESULTADO PRELIMINAR DO CONCURSO PÚBLICO DESTINADO AO PROVIMENTO DE CARGOS - PREFEITURA MUNICIPAL DE SANTO ÂNGELO/RS Edital de Concurso: Nº 42/SMAd/2019 Cargo: 1-Administrador Inscrição Nome do Candidato Nota 7.104 ANDERSON DANIEL STOCHERO 79,00 4.124 ANDERSON LUIS BURKHARD 61,50 4.027
    [Show full text]
  • Procalcitonin-Guided Interventions Against Infections to Increase Early Appropriate Antibiotics and Improve Survival in the Intensive Care Unit: a Randomized Trial
    Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: A randomized trial Jens U. Jensen, MD, PhD; Lars Hein, MD; Bettina Lundgren, MD, DMSc; Morten H. Bestle, MD, PhD; Thomas T. Mohr, MD, PhD; Mads H. Andersen, MD; Klaus J. Thornberg, MD; Jesper Løken, MD; Morten Steensen, MD; Zoe Fox, MD, PhD; Hamid Tousi, MD; Peter Søe-Jensen, MD; Anne Ø. Lauritsen, MD; Ditte Strange, MD; Pernille L. Petersen, MD; Nanna Reiter, MD; Søren Hestad, MD; Katrin Thormar, MD; Paul Fjeldborg, MD; Kim M. Larsen, MD; Niels E. Drenck, MD; Christian Østergaard, MD, PhD, DMSc; Jesper Kjær, MSc; Jesper Grarup, DVM; Jens D. Lundgren, MD, DMSc; for the The Procalcitonin And Survival Study (PASS) Study Group Objective: For patients in intensive care units, sepsis is a were supplemented with a drug-escalation algorithm and inten- common and potentially deadly complication and prompt initia- sified diagnostics based on daily procalcitonin measurements. tion of appropriate antimicrobial therapy improves prognosis. The Measurements and Main Results: The primary end point was objective of this trial was to determine whether a strategy of death from any cause at day 28; this occurred for 31.5% (190 of antimicrobial spectrum escalation, guided by daily measurements 604) patients in the procalcitonin arm and for 32.0% (191 of 596) of the biomarker procalcitonin, could reduce the time to appro- patients in the standard-of-care-only arm (absolute risk reduc- priate therapy, thus improving survival. tion, 0.6%; 95% confidence interval [CI] ؊4.7% to 5.9%). Length ؍ Design: Randomized controlled open-label trial.
    [Show full text]
  • CHEMISTRY and IMMUNOASSAY ANALYZERS JULY 2018 | CAP TODAY 49
    CHEMISTRY AND IMMUNOASSAY ANALYZERS JULY 2018 | CAP TODAY 49 Part 1 of 15 Arlington Scientific Arlington Scientific Beckman Coulter Mike LaDow [email protected] Mike LaDow [email protected] Wendy Rodriguez [email protected] FOR MID– AND HIGH–VOLUME Springville, UT Springville, UT Brea, CA LABORATORIES 801-489-8911 www.arlingtonscientific.com 801-489-8911 www.arlingtonscientific.com 714-961-6679 www.beckmancoulter.com Name of instrument ASI Evolution Automated RPR Analyzer ASI Infinity EIA Analyzer DxC 700 AU Type of instrument immunoassay immunoassay chemistry Operational type/Model type batch/benchtop batch/benchtop continuous random access/floor standing List price/First year sold in U.S. $44,995/2018 $44,995/1998 —/2016 Targeted hospital bed size/Targeted daily test volume ≥20/>100 ≥20/20 —/300–2,250 samples Company manufactures instrument yes (also sold by Fisher Scientific, VWR) yes (also sold by Fisher Scientific, VWR) yes (also sold by Henry Schein, McKesson, Medline) Other models in this family of analyzers — — AU 480, AU 5800 No. of units in clinical use in U.S./Outside U.S. (countries) 4/— 80/4,350 58/100 Dimensions (H × W × D)/Instrument footprint (square feet) 19 × 36 × 22 in./6 sq. ft. 19 × 36 × 22 in./6 sq. ft. 51 × 78 × 41 in./40.1 sq. ft. Weight empty/Weight fully loaded 78 lbs./80 lbs. 78 lbs./80 lbs. 1,046 lbs./— Tests available on analyzer in U.S. ASI automated rapid plasma reagin test for syphilis for ASI infectious disease tests: VZV, EBV-VCA, rubella, CMV, complete general chemistry, proteins/serology, thyroid, diagnostic and blood donor screening EBV-NA, HSV, toxoplasma, measles, mumps; open tests esoterics, TDM, DAT panels, more from other manufacturers Tests not available in U.S.
    [Show full text]